匹多莫德联合孟鲁司特对支气管哮喘患儿的疗效及肺功能影响的临床研究

Clinical Efficacy and Pulmonary Function Research of Pidotimod Combined with Montelukast in Treatment of Children with Bronchial Asthma

目的探讨匹多莫德联合孟鲁司特对支气管哮喘患儿的临床疗效及肺功能的影响。方法选取2014年1月至2015年1月我院收治的支气管哮喘患儿150例,随机分为对照组和观察组,每组各75例,前者给予口服孟鲁司特进行治疗,后者在口服孟鲁司特基础上再加用匹多莫德进行治疗,治疗3个月后,比较两组患儿的临床疗效、不良反应发生情况,并对两组患儿进行随访,观察患儿的哮喘发作次数、持续时间以及呼吸道感染发生次数,对比分析两组患儿治疗前、后日间咳嗽与夜间咳嗽症状评分情况以及肺功能指标的变化情况。结果治疗后,观察组患儿治疗总有效率明显高于对照组患儿治疗总有效率(P<0.05),而不良反应发生率显著低于对照组(P<0.05);观察组患儿日间咳嗽症状评分、夜间咳嗽症状评分、第1s用力呼气量及峰值呼气流速均较治疗前显著改善(P<0.01;P<0.01;P<0.05;P<0.01),且优于对照组(P均<0.05);随访患儿3个月,观察组患儿哮喘平均发作次数以及呼吸道感染次数明显少于对照组,且哮喘持续时间明显短于对照组(P<0.05;P<0.01;P<0.01)。结论匹多莫德联合孟鲁司特治疗支气管哮喘疗效显著,可有效改善患儿的肺功能,且不良反应发生较少,值得在临床上推广应用。

Objective To explore the clinical efficacy of pidotimod combined with montelukast and effect on pulmonary function in children with bronchial asthma. Methods A total of 150 children with bronchial asthma in our Hospital from 2014 to 2015 were selected and divided into the control group and the observation group. The control group（ 75 cases） was treated with oral administration of montelukast,while the observation group（ 75 cases） was treated with pidotimod on the basis of the control group. After three months of treatment,the clinical efficacy,adverse reactions and the incidence of asthma attack,duration and respiratory tract infection were compared between the two groups,the cough symptom scores in day and night and pulmonary function before and after treatment were compared. Results The total effective rate of the observation group was significantly higher than that of control group（ P〈0. 05）. The incidence of adverse reactions in observation group was significantly lower than that of control group（ P〈0. 05）. After treatment,the cough symptom scores in day and night,the amount of forced expiratory volume in the first second and peak expiratory flow rate of the observation group were significantly improved compared with before treatment（ P〈0. 01; P〈0. 01; P〈0. 05; P〈0. 01）.The scores of cough in the observation group were significantly lower than those of the control group,and the peak expiratory flow rate was significantly higher than thatof control group（ P〈0. 05）. During the follow-up period of three months,the average number of asthma attack,the duration and the number of respiratory tract infection in the observation group were significantly lower than those of the control group（ P〈0. 05; P〈0. 01;P〈0. 01）. Conclusion The therapeutic effect of pidotimod combined with montelukast on children with bronchial asthma is obvious,which can effectively improve the lung function,decrease the occur of adverse reactions.